Status:
COMPLETED
Metabolic Effects of Paricalcitol
Lead Sponsor:
University of Washington
Collaborating Sponsors:
Abbott
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease...
Detailed Description
Persons with chronic kidney disease (CKD) are at markedly increased risk of death, particularly from cardiovascular disease (CVD). A number of metabolic abnormalities may contribute to adverse health ...
Eligibility Criteria
Inclusion
- Estimated glomerular filtration rate of 15-59 mL/min/1.73m2
- Fasting glucose 100-125 mg/dL
- 18 years and older
Exclusion
- Diagnosed with diabetes mellitus
- Use of diabetes medications (insulin or oral hypoglycemics)
- Prior dialysis or transplantation
- Planning to leave the area within 6 months
- Participation in another clinical trial within 30 days
- Treatment with paricalcitol, calcitriol, or corticosteroids in the preceding 8 weeks
- Serum calcium more than 10.2 mg/dL
- Pregnancy or breast-feeding
- Change in dose (within 8 weeks) of Fibrates, Niacin, ACE inhibitors, Angiotensin receptor blockers, Thiazide diuretics, Beta-blockers, Cholecalciferol or Ergocalciferol
- Incontinent of urine
- Cancer (other than skin cancer) within 5 years
- Tuberculosis
- Sarcoidosis
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01003275
Start Date
October 1 2009
End Date
November 1 2011
Last Update
April 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington
Seattle, Washington, United States, 98195